ArticleJournal of the American Academy of DermatologyPublished
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Journal of the American Academy of Dermatology
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Skin Neoplasms; Psoriasis; Dermatologic Agents; Treatment Outcome; Severity of Illness Index; Follow-Up Studies; Double-Blind Method; Uterine Cervical Neoplasms; Female; Antibodies, Monoclonal, Humanized; Adalimumab
- PubMed ID
- 37019386
- Added to directory
- Source checked